Interpretation of the 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty
10.3760/cma.j.cn121113-20230330-00176
- VernacularTitle:2022年ACR/AAHKS风湿性疾病患者择期全髋或全膝关节置换术围手术期抗风湿类药物管理指南解读
- Author:
Songlin LI
1
;
Wenwei QIAN
;
Qian WANG
;
Xisheng WENG
;
Jin LIN
;
Jin JIN
;
Xinping TIAN
;
Huiming PENG
;
Bin FENG
;
Xiaofeng ZENG
Author Information
1. 中国医学科学院北京协和医学院北京协和医院骨科，北京 100050
- Keywords:
Rheumatic diseases;
Arthroplasty, replacement;
Guidebook
- From:
Chinese Journal of Orthopaedics
2023;43(13):928-932
- CountryChina
- Language:Chinese
-
Abstract:
The American College of Rheumatology (ACR) and the American Association of Hip and Knee Surgeons (AAHKS) convened a writing group to develop a consensus report on the management of anti-rheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty in June 2022. In particular, the consensus provides significant updates on target synthetic disease modifying anti-rheumatic drugs and perioperative medication management in patients with systemic lupus erythematosus, as well as the addition of newly approved antirheumatic medications for administration. This article will interpret the consensus and provide a reference for the perioperative management of antirheumatic medications for hip and knee arthroplasty in patients with rheumatic diseases in China.
